A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom?

Chi Un Pae, David M. Marks, Changsu Han, Ashwin A. Patkar

Research output: Contribution to journalLetterpeer-review

5 Scopus citations
Original languageEnglish
Pages (from-to)1087-1088
Number of pages2
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume32
Issue number4
DOIs
StatePublished - 15 May 2008

Bibliographical note

Funding Information:
Dr. Pae has received research grant from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Jansssen Pharmaceutcals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka Korea, Wyeth Korea, and Korean Institute of Science and Technology Evaluation and Planning; has received honoraria and is on the speaker's bureaus of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Jansssen Pharmaceutcals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty Inc, and Otsuka Korea. Dr. Han has received research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013-E00033) and from Korea University Neuropsychiatric Alumni Grant. Dr. Marks has no financial disclosures. Dr. Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; is on the speaker's bureau of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; has received research support from National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty Inc, Organon, Jazz Pharmaceuticals, and Pfizer.

Cite this